Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Helicases | 7 | 2025 | 149 | 1.850 |
Why?
|
| DNA-Binding Proteins | 7 | 2025 | 1421 | 1.330 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2025 | 95 | 0.920 |
Why?
|
| Colorectal Neoplasms | 4 | 2025 | 746 | 0.900 |
Why?
|
| Molecular Targeted Therapy | 2 | 2025 | 385 | 0.800 |
Why?
|
| Neoplasms | 5 | 2025 | 2464 | 0.750 |
Why?
|
| Cell Plasticity | 1 | 2021 | 27 | 0.710 |
Why?
|
| Clonal Evolution | 1 | 2020 | 38 | 0.660 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 73 | 0.650 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 2051 | 0.630 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 345 | 0.580 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2025 | 199 | 0.550 |
Why?
|
| Drug Synergism | 2 | 2025 | 359 | 0.440 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 2132 | 0.430 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 3184 | 0.410 |
Why?
|
| Cell Survival | 2 | 2024 | 1077 | 0.320 |
Why?
|
| DNA Damage | 3 | 2024 | 364 | 0.280 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 90 | 0.250 |
Why?
|
| TCF Transcription Factors | 2 | 2020 | 16 | 0.210 |
Why?
|
| Drug Discovery | 2 | 2022 | 130 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 814 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 191 | 0.190 |
Why?
|
| Carbon Monoxide | 2 | 2018 | 68 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 24 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 226 | 0.160 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 224 | 0.160 |
Why?
|
| Histones | 1 | 2023 | 586 | 0.150 |
Why?
|
| Cytosol | 1 | 2018 | 214 | 0.140 |
Why?
|
| Logic | 1 | 2017 | 5 | 0.140 |
Why?
|
| Flavonols | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2025 | 2344 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 105 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 421 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 809 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 386 | 0.130 |
Why?
|
| Down Syndrome | 1 | 2022 | 469 | 0.120 |
Why?
|
| Humans | 15 | 2025 | 128417 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 185 | 0.120 |
Why?
|
| Animals | 6 | 2025 | 34479 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 888 | 0.100 |
Why?
|
| Energy Metabolism | 1 | 2018 | 831 | 0.100 |
Why?
|
| Mitochondria | 1 | 2018 | 848 | 0.100 |
Why?
|
| Drug Design | 2 | 2022 | 154 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 195 | 0.080 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 471 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 16602 | 0.060 |
Why?
|
| Female | 4 | 2025 | 68153 | 0.060 |
Why?
|
| Poly ADP Ribosylation | 1 | 2023 | 8 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2024 | 197 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 1404 | 0.050 |
Why?
|
| Apoptosis | 2 | 2024 | 2435 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 39 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2023 | 217 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 92 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 109 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 209 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 87 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2019 | 43 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2019 | 199 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 86 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 312 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 104 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 657 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 134 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 165 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 530 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 58 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 853 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1281 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2017 | 102 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 881 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 464 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1559 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2022 | 1176 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1181 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 3937 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2022 | 4001 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1351 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2675 | 0.030 |
Why?
|
| Oxygen | 1 | 2017 | 899 | 0.020 |
Why?
|